Risk wording should not minimize the severity of a risk event
Rule
Risk wording should accurately reflect the seriousness of the risk; framing that minimizes the severity of a risk event may cause the piece to be considered false or misleading.
Check
Compare the risk statement's wording (e.g., 'some patients experienced X') against the underlying labeling data (e.g., boxed warning language) for understatement of the risk's seriousness.
Escalate when
Whenever a risk phrase could plausibly read as softer in severity than what the labeling data shows.
Where this comes from
Section III.A.3, Framing Risk Information · page 12. The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.
…’s device or drug class. > Example 7: If the benefit information refers to the brand name, “Drug X,” then “Common side > effects associated with Drug X” would be preferable to “Common side effects associated with > [the generic name].” Moreover, within the risk information presentation, phrases such as “Like all medicines, Drug X has some side effects,” may have the effect of minimizing the risks that follow. Framing risk information in a way that minimizes the severity of a risk event may also cause a promotional piece to be considered false or misleading. > Example 8: If a drug’s package insert contains a boxed warning about the risk of life-threatening > fevers associated with its use and reports that 55 percent of patients taking the drug experience > dizziness, a statement such as “Adverse events associated with drug X include fevers. Some > patients experienced dizziness” misleadingly describes the risk profile of the drug by failing to > convey the seriou…
- Document
- FDA guidance: Presenting Risk Information in Prescription Drug and Medical Device Promotion (see document)
- Version
- as retrieved — the publisher does not version this document; the fingerprint below identifies the exact file
- Retrieved
- 2026-09-21 from www.fda.gov
- Fingerprint
- f5654ab082f6cd4408143f16…
FDA guidance describes the agency's current thinking. It is not binding law, and this rule is a recommendation, not an obligation.